Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- PNT
- Price
- -
- Stock movement up
- +- (%)
- Company name
- POINT Biopharma Global Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.33B
- Ent value
- 1.36B
- Price/Sales
- 5.47
- Price/Book
- 3.14
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- 403.06%
- Trailing P/E
- 13.80
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 85.19%
- 3 year return
- -4.45%
- 5 year return
- -
- 10 year return
- -
Last updated: 2024-12-17
DIVIDENDS
PNT does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 13.80 |
| Price to OCF | 11.89 |
| Price to FCF | 14.36 |
| Price to EBITDA | 13.39 |
| EV to EBITDA | 13.71 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 5.47 |
| Price to Book | 3.14 |
| EV to Sales | 5.60 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 106.57M |
| EPS (TTM) | 0.91 |
| FCF per share (TTM) | 0.88 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 243.69M |
| Gross profit (TTM) | 9.69B |
| Operating income (TTM) | 107.77M |
| Net income (TTM) | 96.55M |
| EPS (TTM) | 0.91 |
| EPS (1y forward) | -0.84 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 3976.93% |
| Operating margin (TTM) | 44.23% |
| Profit margin (TTM) | 39.62% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 21.61M |
| Net receivables | 9.39M |
| Total current assets | 353.25M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 63.13M |
| Total assets | 477.70M |
| Accounts payable | 8.89M |
| Short/Current long term debt | 10.66M |
| Total current liabilities | 38.67M |
| Total liabilities | 53.51M |
| Shareholder's equity | 424.19M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 112.06M |
| Capital expenditures (TTM) | 19.32M |
| Free cash flow (TTM) | 92.74M |
| Dividends paid (TTM) | 373.78M |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 22.76% |
| Return on Assets | 20.21% |
| Return on Invested Capital | 22.66% |
| Cash Return on Invested Capital | 21.76% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| PNT | S&P500 | |
| Current price drop from All-time high | -25.86% | -0.50% |
| Highest price drop | -71.35% | -56.47% |
| Date of highest drop | 16 Dec 2021 | 9 Mar 2009 |
| Avg drop from high | -41.86% | -10.99% |
| Avg time to new high | 219 days | 12 days |
| Max time to new high | 726 days | 1805 days |
COMPANY DETAILS
Marketcap
1.33B
Marketcap category
Small-cap
Description
POINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-alpha inhibitor targeting program being developed for use in various tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana. As of December 27, 2023, POINT Biopharma Global Inc. operates as a subsidiary of Eli Lilly and Company.
Employees
129
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner